NCT07358156Active, not recruitingPhase 1
A study to compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 with US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Jul 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 335 (estimated)
- First submitted
- 29 Oct 2025
- Start date
- 14 Jan 2026
- Lead sponsor
- Chong Kun Dang Pharmaceutical Corp.
- Diseases
- Atopic dermatitis (eczema), Asthma, COPD
- EU CT number
- 2025-523115-11-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 335
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Parexel International GmbH Coordinator of this site? Confirm its status | Berlin | Germany | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.